Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06047379
Title	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Neonc Technologies, Inc.
Indications	squamous cell carcinoma melanoma lung small cell carcinoma renal cell carcinoma Merkel cell carcinoma colorectal cancer astrocytoma, IDH-mutant, grade 3 astrocytoma, IDH-mutant, grade 2 cervical cancer Advanced Solid Tumor esophagus squamous cell carcinoma lung non-small cell carcinoma stomach cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma esophageal cancer astrocytoma, IDH-mutant, grade 4 transitional cell carcinoma IDH-wildtype glioblastoma
Therapies	NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Precision NextGen Oncology	RECRUITING	Beverly Hills	California	90212	United States	Details
Northwest Medical Specialties	RECRUITING	Tacoma	Washington	98405	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field